igorua-shutterstock-com-patent-
IgorUA / Shutterstock.com
24 October 2016Americas

Astellas sues Apotex for patent infringement

Japanese drug company Astellas has filed a complaint against Canada-based Apotex for allegedly infringing its patents centring on the drug Myrbetriq (mirabegron).

Myrbetriq is a treatment for patients with an overactive bladder.

The case, which was filed on Friday, October 21, in the US District Court for the District of Delaware, arose after Apotex filed an Abbreviated New Drug Application with the Food and Drug Administration, seeking approval to manufacture a generic version of the drug before the expiration of the patents involved.

Apotex has allegedly infringed four patents, which are 7,342,117; 7,982,049; 8,835,474, and RE44,872.

Astellas has asked the court to declare that its patents are valid.

It has also asked for a permanent injunction restraining Apotex from bringing the generic drug to market, as well as an award of costs and expenses for bringing the case to court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
16 February 2018   Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.

More on this story

Americas
16 February 2018   Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.

More on this story

Americas
16 February 2018   Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.